Show Summary Details
Page of

Nephrogenic systemic fibrosis 

Nephrogenic systemic fibrosis
Chapter:
Nephrogenic systemic fibrosis
Author(s):

Teresa K. Chen

and Derek M. Fine

DOI:
10.1093/med/9780199579655.003.0170
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 05 August 2020

1. NSF can be a devastating disorder resulting in excruciating pain and/or severe disability.

2. Gadolinium triggers NSF.

3. Not all GBC agents are created equal. Risk of NSF is dependent on the individual stability of each GBC agent.

4. The prolonged half-life of GBC agents in renal failure (GFR <30 ml/min/1.73m2) predisposes to NSF by allowing for dissociation of toxic free gadolinium.

5. The deposition of gadolinium in tissue triggers a cascade of events culminating in the clinical presentation of NSF.

6. Treatments for NSF are limited and still being investigated. Until then, our best defence against NSF is prevention.

7. For those with NSF, physical and occupational therapy are critical in maintaining functional status.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.